Actively Recruiting
Intratumoral CAN2109 in Subjects With Solid Tumors
Led by Canwell Biotech Limited · Updated on 2024-12-19
27
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
CONDITIONS
Official Title
Intratumoral CAN2109 in Subjects With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent and comply with study requirements
- Male or female aged 18 years or older at screening
- Metastatic or locally advanced solid tumor progressed on, refractory to, or lacking effective standard therapy; preferred tumors include skin carcinoma, melanoma, Merkel cell carcinoma, breast cancer, head and neck squamous cell carcinoma, sarcoma, cervical carcinoma, and colorectal cancer
- ECOG Performance Status of 0-1
You will not qualify if you...
- Unresolved toxicities from prior therapy not resolved to CTCAE v5.0 Grade 0 or 1, except endocrinopathies, alopecia, and vitiligo
- Treatment with systemic corticosteroids exceeding 10 mg/day prednisone or equivalent
- Active infection requiring systemic therapy
- Unstable or inadequate cardiac function including NYHA Class 3 or 4 heart failure, uncontrolled hypertension, recent acute coronary syndrome, important cardiac arrhythmia, or QTc interval > 480 ms
- History of interstitial lung disease
- History of coagulopathy causing uncontrolled bleeding or bleeding disorders
- Participation in another investigational study within 30 days
- Known psychiatric, substance abuse, or other disorders interfering with study cooperation
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-Sen University Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China, 510535
Actively Recruiting
Research Team
H
Herui Yao, MD
CONTACT
E
Erwei Song, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here